European COVID-19 antibody enters Phase III testing

Acording to Saye Khoo, Chief Investigator for the study, " VIR-7832 appears to stand up to the major circulating variants of SARS-CoV-2 in the UK and look for early signals of antiviral activity and enhanced immune response to infection.” According to interim results of clinical testing within the US ACTIV programme, the antibody showed an efficacy of more than 80%. However, according to information published by the NIH, the trial was stopped later in the US.

AGILE is a clinical trial platform supported launched by the UK government in July 2020 that uses adaptive trial design. VIR-7832, will be given to patients who have tested positive for COVID-19 and have mild to moderate symptoms. Based on pre-clinical data, VIR-7832 has three potential mechanisms of action: it can neutralize the virus; target already infected cells for destruction by the immune system; and, it can stimulate a T cell response that can further control the infection.